Good News for Kids With Peanut Allergies: Smaller Doses Work Just as Well

Children with peanut allergies can build resistance with much smaller doses than previously thought, according to groundbreaking research from The Hospital for Sick Children in Montreal. The study found that a maintenance dose of just 30 milligrams of peanut—about one-tenth the standard amount—worked just as effectively as 300-milligram doses for oral immunotherapy, while causing fewer uncomfortable side effects.

How Does Low-Dose Peanut Therapy Work?

Oral immunotherapy involves gradually feeding children increasing amounts of the allergen they're sensitive to, helping their immune system build tolerance over time. In this approach, kids eventually reach a "maintenance" dose that they consume regularly to maintain their improved tolerance levels.

The research team randomly assigned 51 children to receive either the low 30-milligram dose, the standard 300-milligram dose, or to avoid peanuts entirely. Both treatment groups showed significant and similar improvements in their allergic reaction thresholds, proving that even tiny amounts can make a meaningful difference.

What Are the Key Benefits of Lower Doses?

The smaller doses offered several important advantages that could make treatment more accessible for families:

• Fewer Side Effects: Children taking the low dose experienced significantly fewer uncomfortable reactions during treatment
• Better Taste Tolerance: The small amount is manageable even for children who dislike the taste of peanuts
• Flexible Treatment Options: Families can choose to stay on very low doses or gradually increase over time based on their goals

"We were excited to find that peanut oral immunotherapy maintenance doses can be much lower than previously thought and still contribute to positive outcomes," said lead researcher Dr. Julia Upton, head of immunology and allergy at The Hospital for Sick Children.

Could Even Smaller Doses Be Effective?

The researchers believe their findings may just be the beginning. "This is the first time we've compared standard doses to such a low dose, but the minimum maintenance dose to provide benefit may be even lower than 30 mg," explained senior researcher Dr. Thomas Eiwegger, an adjunct scientist in the translational medicine program at The Hospital for Sick Children.

This flexibility could revolutionize how families approach peanut allergy treatment. Some might choose to remain on very low doses for long-term management, while others could use the low-dose approach as a stepping stone to higher amounts, depending on their comfort level and treatment goals.

"The more options we have, the more we can support patients' experience and provide meaningful, tailored care," Upton noted. This personalized approach could make oral immunotherapy accessible to more families who previously found the side effects of higher doses too challenging to manage.